These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3804907)

  • 21. Teicoplanin pharmacokinetics in patients with chronic renal failure.
    Bonati M; Traina GL; Villa G; Salvadeo A; Gentile MG; Fellin G; Rosina R; Cavenaghi L; Buniva G
    Clin Pharmacokinet; 1987 Apr; 12(4):292-301. PubMed ID: 2954735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disopyramide kinetics in renal impairment: determinants of interindividual variability.
    Burk M; Peters U
    Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.
    Moellering RC; Krogstad DJ; Greenblatt DJ
    Ann Intern Med; 1981 Mar; 94(3):343-6. PubMed ID: 6101256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of cefpiramide in healthy volunteers, patients with various degrees of renal dysfunction, and patients on hemodialysis.
    Ohkawa M; Tokunaga S; Sugata T; Shimamura M; Okasho A; Hirano S; Matsui H
    Chemotherapy; 1989; 35(6):416-22. PubMed ID: 2612231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.
    Dimmitt DC; Shah AK; Arumugham T; Cramer MB; Halstenson C; Horton M; Weir SJ
    J Clin Pharmacol; 1998 Sep; 38(9):798-806. PubMed ID: 9753207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function.
    Ohkawa M; Orito M; Sugata T; Shimamura M; Sawaki M; Nakashita E; Kuroda K; Sasahara K
    Antimicrob Agents Chemother; 1980 Sep; 18(3):386-9. PubMed ID: 6932824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function.
    Kowalsky SF; Echols RM; Venezia AR; Andrews EA
    Antimicrob Agents Chemother; 1983 Aug; 24(2):151-5. PubMed ID: 6314884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients.
    Agersø H; Seiding Larsen L; Riis A; Lövgren U; Karlsson MO; Senderovitz T
    Br J Clin Pharmacol; 2004 Oct; 58(4):352-8. PubMed ID: 15373927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of TZU-0460, a new H2-receptor antagonist, in patients with impaired renal function.
    Takabatake T; Ohta H; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Satoh S; Hattori N
    Eur J Clin Pharmacol; 1986; 30(6):709-12. PubMed ID: 2876900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosage regimen of ranitidine in patients with renal impairment.
    Ebihara A; Ohashi K; Ikeda T; Yuhara M; Tagawa H; Yamakado M; Asano Y; Tabei K; Nakazawa K; Kondo K
    Int J Clin Pharmacol Res; 1989; 9(1):1-7. PubMed ID: 2707920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.
    Jaehde U; Sörgel F; Reiter A; Sigl G; Naber KG; Schunack W
    Clin Pharmacol Ther; 1995 Nov; 58(5):532-41. PubMed ID: 7586947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis.
    Gambertoglio JG; Alexander DP; Barriere SL
    Antimicrob Agents Chemother; 1984 Dec; 26(6):845-9. PubMed ID: 6098220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of Cytembena in chronic renal impairment.
    Schück O; Grafnetterová J; Sotorník I
    Neoplasma; 1976; 23(2):161-70. PubMed ID: 947088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of renal function on risedronate pharmacokinetics after a single oral dose.
    Mitchell DY; St Peter JV; Eusebio RA; Pallone KA; Kelly SC; Russell DA; Nesbitt JD; Thompson GA; Powell JH
    Br J Clin Pharmacol; 2000 Mar; 49(3):215-22. PubMed ID: 10718776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of ciprofloxacin in liver cirrhosis.
    Ruhnke M; Trautmann M; Borner K; Hopfenmüller W
    Chemotherapy; 1990; 36(6):385-91. PubMed ID: 2292201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of renal disease on the pharmacokinetics of diethylcarbamazine in man.
    Adjepon-Yamoah KK; Edwards G; Breckenridge AM; Orme ML; Ward SA
    Br J Clin Pharmacol; 1982 Jun; 13(6):829-34. PubMed ID: 7093114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution kinetics of netilmicin in human blister fluid: effect of renal impairment.
    Lanao JM; López A; Domínguez-Gil A; Martin J; Gómez JR; Tabernero JM
    Biopharm Drug Dispos; 1991 Mar; 12(2):149-62. PubMed ID: 2031996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of metioprim in normal subjects and patients with impaired renal function.
    Vergin H; Bishop-Freudling GB; Kaiser W; Köhler M; Strobel K; Reutter FW
    Antimicrob Agents Chemother; 1983 Aug; 24(2):190-3. PubMed ID: 6638987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.